SGLT2 inhibitors vs placebo were associated with reduced heart failure hospitalization among patients with history of myocardial infarction.

Research in mice identifies protein responsible for regulating gut movement in response to pressure, exercise, and ...

Researchers have uncovered a stealth survival strategy that melanoma cells use to evade targeted therapy, offering a promising new approach to improving treatment outcomes.

Researchers have uncovered a stealth survival strategy that melanoma cells use to evade targeted therapy, offering a ...

Are you ignoring the early signs of kidney disease in diabetes? As diabetic kidney disease is on the rise, here’s what ...

Adults with overweight or obesity and type 2 diabetes who are given the sodium glucose cotransporter 2 (SGLT-2) inhibitor drug dapagliflozin alongside moderate calorie restriction achieve much higher ...

In a trial, sotagliflozin use in patients with diabetes and chronic kidney disease (CKD) was associated with lower risk of ischemic cardiovascular outcomes.

Empagliflozin patent expiration in India leads to affordable treatment for diabetes, heart failure, and kidney disease.

BACKGROUND: Despite the high morbidity and mortality of heart failure with preserved ejection fraction (HFpEF), treatment ...

Sodium–glucose cotransporter-2 inhibitors (SGLT2i) are now recommended for persons with CKD with and without diabetes for both kidney and cardiovascular benefit. The guidelines also recommend statins ...

ABSTRACT: Background: Euglycemic Diabetic Ketoacidosis (EDKA) is a rare but well-known adverse effect of sodium glucose transporter 2 (SGLT-2) inhibitors. This class of antidiabetic medications has ...

But this class of medicine, called SGLT-2 inhibitors, blocks this process and brings down ... “While they were initially prescribed for patients with kidney disease because of their mechanism of ...